The case for primary prevention of obesity in the era of GLP-1 therapies
Soren Holm, Manuel Tena-Sempere, Dimitrios Koutsouris, George V. Dedoussis et autres
Obesity rates continue to rise across Europe, driven by obesogenic environments shaped by food systems, urban design, socioeconomic inequalities, and commercial forces. The introduction of incretin-based pharmacotherapies like GLP-1 receptor agonists has transformed treatment, leading to significant weight loss and metabolic benefits …
no, gb, es, gr, at, fr, lu, pt, nl (code pays fourni par la source)
1 citation
The Lancet Regional Health - Europe